by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials
A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point. A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile. Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Multiple myeloma treatment is advancing with the advent of bispecific antibody drugs, which use the patient’s T cells to fight the disease. Myeloma Center physicians and researchers Carolina Schinke, M.D., and Samer Al Hadidi, M.D., M.S., are leading clinical...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Discover how AI is reshaping medical research, streamlining clinical trials and improving patient outcomes with Medidata Clinical Data Studio. Discover how AI is reshaping medical research, streamlining clinical trials and improving patient outcomes with Medidata...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by MS Focus: the Multiple Sclerosis Foundation and affiliated groups. National MS Education and Awareness Month is celebrated each year in the...
